Category: General Biotechnology

The commercial prospects of biogenerics – how much will they save?

This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the status of biogenerics, background on the key issues, and the impacts on the industry of the various possible approval schemes. Clinical Trials The clinical trial requirement for biogenerics is the leading issue from a regulatory […]




Click here for reuse options!
Copyright 2007 Biotechblog

VCs filling biotech funding gap

If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists will tell you that they have different investment philosophies than everyone else, they’ll tell you that they’re not venture capitalists, they’ll tell you that they focus on areas that everyone else ignores. So, it should […]




Click here for reuse options!
Copyright 2007 Biotechblog

Angels filling biotechnology funding gap

Biotechnology companies have been facing a widening funding gap. Between frozen federal research budgets and a growing focus among venture capitalists and senior partners for larger, more mature, biotechnology firms – at the expense of smaller ones – a funding gap is growing between basic research and initial proof-of-principle commercial research. So, who fills the […]




Click here for reuse options!
Copyright 2007 Biotechblog

Looking beyond traditional markets

The United States is the world’s largest pharmaceutical market. Japan is the second largest, although the combined European Union is larger than the Japanese market (but smaller than the U.S.). Naturally, any company looking to sell drugs should focus on these markets, but there are reasons to reach out into smaller markets: This article describes […]




Click here for reuse options!
Copyright 2007 Biotechblog

Price controls and compulsory licensing give buyers more power … for a price.

Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized compulsory licensing, which enables a country to produce generic versions of branded drugs if they face a health crisis without violating international patent agreements. The United States threatened to use compulsory licensing to acquire cheap […]




Click here for reuse options!
Copyright 2007 Biotechblog

Carnival of Biotechnology

Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in drug companies as they progress through clinical trials. Ted Love, CEO of Nuvelo Inc., explains how biotechnology companies are frequently able to recover from seemingly disastrous clinical trial failures. Patents When manufacturers seeking to sell […]




Click here for reuse options!
Copyright 2007 Biotechblog

Why are biogenerics so hard to regulate?

There’s been a lot of press floating around lately about the push to develop a framework for biogeneric (or biosimilar, or follow-on, etc.) approvals. Why are biogenerics so hard to regulate? Why can’t they just follow the same path as traditional generic drugs? The answer lies in their size and complexity. I’ll use the following […]




Click here for reuse options!
Copyright 2007 Biotechblog

Drug Patent Expirations in March 2007

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in March 2007 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration BUDESONIDE Astrazeneca budesonide 4,907,583 MAR 13,2007 FEMPATCH Parke Davis estradiol 4,906,463 MAR 06,2007 GLYNASE Pharmacia And Upjohn glyburide 4,735,805 MAR 11,2007 LOTREL Novartis amlodipine besylate; benazepril hydrochloride 4,879,303 MAR 25,2007 VIDEX […]




Click here for reuse options!
Copyright 2007 Biotechblog

Open Biotechnology Journal

I’ve been invited to join the editorial board of the nascent Open Biotechnology Journal. The Open Biotechnology Journal is a peer-reviewed open access journal and aims to publish original research papers in all core areas of biotechnology including basic and applied research, e.g, molecular engineering of nucleic acids and proteins; molecular therapy; imaging technology and […]




Click here for reuse options!
Copyright 2007 Biotechblog

Carnival of Biotechnology

Scientific Advances The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920, elucidated insulin’s central role in diabetes. The most recent discovery, also from the University of Toronto, has found a strong link between diabetes, pain nerves, and inflammation. Researchers were able to prevent and even reverse […]




Click here for reuse options!
Copyright 2007 Biotechblog

%d bloggers like this: